Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Allen Bott

Neurology with Special Qualifications in Child Neurology Oakland, CA Medical Doctor

NPI 1770577652 CMS profile 215992

3120 Webster St, Oakland, CA 94609

Open in the dashboard

General payments

$371,554

563 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Allen Bott of Oakland, CA is reported in the CMS Open Payments database as having received $371,554 across 563 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Neurology with Special Qualifications in Child Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $84,647 126
2024 General $29,622 44
2023 General $37,334 54
2022 General $33,720 32
2021 General $51,344 65
2020 General $58,158 85
2019 General $76,729 157

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Allen Bott
  • Neurology with Special Qualifications in Child Neurology median
  • Middle half of Neurology with Special Qualifications in Child Neurology
  • National median

In program year 2025, general payments to Allen Bott were reported at $84,647. Among 1,228 Neurology with Special Qualifications in Child Neurology profiles paid that year, the median was $276 and the middle half received between $87 and $1,522.

Show as a table
Year Allen Bott Neurology with Special Qualifications in Child Neurology median Middle half National median
2019 $76,729 $262 $68–$1,313 $163
2020 $58,158 $188 $46–$1,222 $114
2021 $51,344 $183 $45–$1,356 $132
2022 $33,720 $229 $72–$1,177 $149
2023 $37,334 $269 $93–$1,195 $160
2024 $29,622 $300 $98–$1,428 $164
2025 $84,647 $276 $87–$1,522 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Neurocrine Biosciences, Inc. $143,576 175 payments
  2. ITI, Inc. $60,110 78 payments
  3. Axsome Therapeutics, Inc. $39,027 50 payments
  4. Allergan Inc. $34,322 67 payments
  5. Otsuka America Pharmaceutical, Inc. $23,559 42 payments
  6. Eisai Inc. $22,661 27 payments
  7. Teva Pharmaceuticals USA, Inc. $19,164 37 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $14,876 23 payments
  9. AbbVie, Inc. $12,095 42 payments
  10. Sunovion Pharmaceuticals Inc. $1,552 7 payments
  11. Other $611 15 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $269,091 150 payments
  2. Consulting Fee $47,618 16 payments
  3. Travel and Lodging $22,639 150 payments
  4. Honoraria $20,900 5 payments
  5. Food and Beverage $11,032 236 payments
  6. Education $273 6 payments
Products named General payments · program years 2019–2025
  1. INGREZZA Neuropsychiatry $72,571 89 payments
  2. CAPLYTA $60,110 78 payments
  3. Auvelity $39,000 49 payments
  4. INGREZZA Neurology $38,287 65 payments
  5. INGREZZA Neurology $30,617 20 payments
  6. REXULTI $23,559 42 payments
  7. Dayvigo $22,661 27 payments
  8. UBRELVY $17,265 33 payments
  9. Trintellix $14,794 22 payments
  10. VRAYLAR $14,461 31 payments
  11. Other $35,519 108 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 56 drugs

Part D claims

2,314

Median for Neurology: 833

Drug cost

$1,053,611

Median for Neurology: $202,670

Branded share of claims

42.8%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ingrezza Valbenazine Tosylate Brand 51 $407,494
Nuplazid Pimavanserin Tartrate Brand 26 $119,937
Trintellix Vortioxetine Hydrobromide Brand 121 $104,463
Rexulti Brexpiprazole Brand 54 $95,008
Emsam Selegiline Brand 13 $53,050
Vraylar Cariprazine Hcl Brand 31 $43,742
Auvelity Dextromethorphan Hbr/Bupropion Brand 44 $42,947
Ajovy Autoinjector Fremanezumab-Vfrm Brand 25 $31,252
Ubrelvy Ubrogepant Brand 17 $25,346
Caplyta Lumateperone Tosylate Brand 14 $22,619

The 10 drugs with the highest cost, of 56 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$60,943

Medicare's payments for the services billed

Medicare patients

165

Average age 75

Services billed

498

97 women, 68 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%
Depression 52%
Arthritis 51%
Diabetes 26%
Ischemic heart disease 23%
Chronic kidney disease 21%
Osteoporosis 21%
Cancer 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
INGREZZA
  • Neurocrine Biosciences, Inc. $16,205
$16,205 51 —
Auvelity
  • Axsome Therapeutics, Inc. $13,043
$13,043 44 —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $44
$44 — —
CREXONT
  • Amneal Pharmaceuticals LLC $30
$30 — —
Sunosi
  • Axsome Therapeutics, Inc. $28
$28 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

563 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology with Special Qualifications in Child Neurology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record